In Brief: Twin Labs Ocuguard
This article was originally published in The Tan Sheet
Twin Labs Ocuguard: The OTC multivitimin/mineral/antioxidant nutrient capsule, taken twice daily, did not improve the vision in patients with advanced age-related macular degeneration (ARMD) but kept it from getting worse, a study group on the disease concludes. Published in the January issue of the Journal of the American Optometric Association, the 18-month prospective, double-blind, case-controlled study compares Ocuguard to a placebo. The subjects were 71 U.S. veterans in their 70s with advanced ARMD...
You may also be interested in...
Perrigo promotes in pricing, planning
Combe sells most of its OTC brands
Finalization of a settlement between the Federal Trade Commission and Rexall Sundown regarding unsupported cellulite treatment claims for the firm's Cellasene dietary supplement hinges upon approval of two related class action settlements pending in California and Florida, according to FTC